Physician profile
Mark D Edge
NPI 1750372777
$10,415.99
in general payments reported to CMS, 2019-2025
31 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,024 · 2020: $1,000 · 2021: $1,284 · 2022: $1,776 · 2023: $1,780 · 2024: $1,681 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,315 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,314.80 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,604.43 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,802.04 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $989.56 | 2019-2025 | |
| Janssen Biotech, INC. | $870.21 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $709.96 | 2019-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $400.75 | 2019-2025 | Linzess |
| Merck Sharp & Dohme LLC | $351.57 | 2019-2024 | Dificid |
| Ardelyx, INC. | $337.99 | 2023-2025 | Ibsrela |
| Medtronic, INC. | $301.90 | 2022-2024 | Interstim, Signia |
| Madrigal Pharmaceuticals | $275.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $231.52 | 2020-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $188.93 | 2023-2025 | Dupixent |
| Pfizer INC. | $186.66 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $172.63 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $138.09 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $121.24 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $100.36 | 2023-2025 | Sucraid, Sucraid |
| Celgene Corporation | $92.30 | 2022-2024 | Zeposia |
| Genzyme Corporation | $91.39 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $88.54 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $86.45 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Celltrion USA INC. | $78.35 | 2024-2025 | Vegzelma, Zymfentra |
| Ipsen Biopharmaceuticals, INC | $49.69 | 2025 | Iqirvo |
| Ambu INC. | $30.23 | 2024 | |
| Boston Scientific Corporation | $28.16 | 2021-2022 | |
| Exact Sciences Corporation | $18.89 | 2025 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $15.73 | 2022 | |
| Aimmune Therapeutics, INC. | $15.67 | 2023 | |
| Fresenius Kabi USA, LLC | $12.95 | 2023 | |
| Organon LLC | $12.47 | 2025 | Hadlima, Renflexis |
| Ferring Pharmaceuticals INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Edge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.